Inflammation Biotech Alumis Trims IPO Plans But Still Raises $250M for Clinical Trials
Immunology and inflammation biotech Alumis has demonstrated its lead drug candidate can hit a certain validated target to treat plaque ...
Immunology and inflammation biotech Alumis has demonstrated its lead drug candidate can hit a certain validated target to treat plaque ...
3:23 PMSpectrum auction ends in just 2 days with bids worth Rs 11,340 croreAn auction of radiowaves that carry voice ...
New Delhi, Allied Blenders and Distillers Ltd, the maker of Officer's Choice Whisky, on Monday said it has raised Rs ...
Tempus AI (TEM) made its trading debut on the Nasdaq via an IPO. The stock has popped in Friday trading ...
The SME IPO of GPES Solar opened for subscription today and will close on June 19. The company aims to ...
The initial public offer (IPO) of Magenta Lifecare was subscribed over 300 times so far on the third day of ...
Ajax Engineering Pvt, an Indian concrete equipment maker backed by Kedaara Capital, is considering an initial public offering that could ...
TripActions CEO Ariel CohenTripActionsThe boss of travel and expense management platform Navan told CNBC he's preparing the company to get ...
Rapport Therapeutics, a young biotech company with technology from the labs of Johnson & Johnson, is now preparing to enter ...
The shares of Indegene will list on the exchanges on Monday and the unlisted market trends indicate robust listing gains ...
Copyright © 2024 EuroAsia24 News.
EuroAsia24 News is not responsible for the content of external sites.